Sengenics is a functional proteomics company that leverages its patented KREX protein folding technology to discover autoantibody biomarker signature for drug response prediction, patient stratification and development of companion diagnostics. Our technology ensure that all microarray proteins are full length, correctly folded and functional, enabling specific and quantitative antibody binding to conformational epitopes.
The company has a global footprint with multiple corporate and research sites across the world with customers and collaborators that include top pharma, biotech and ivy league academic institutions in North America, Europe, and Asia.
Location: United States, Massachusetts, Billerica
Employees: 51-200
Phone: +44 1223 926588
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Summa Equi... | summaequit... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 12.03.2024 | Proteomics Market is growing at a CAGR of 15.15% from 2024 t... | proteomics market The Exactitude Consultancy Proteomics Market Report – Size, Trends, and Forecast 2... | einpresswi... |
| 27.02.2024 | Sengenics Corporation Announces Key Distributor in China | Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofili... | en.prnasia... |
| - | Sengenics Launches AxCESS, a Research Services Suite to Enab... | LONDON--(BUSINESS WIRE)--Mar 2, 2021-- Sengenics, the Functional Proteomics Company, today announced... | oaoa.com/n... |